Eli Lilly and Company - Product Pipeline Review - 2015

  • ID: 3266300
  • Company Profile
  • 251 pages
  • Global Markets Direct
  • Eli Lilly and Company
1 of 4
Eli Lilly and Company - Product Pipeline Review - 2015

Summary

This, ‘Eli Lilly and Company - Product Pipeline Review - 2015’, provides an overview of the Eli Lilly and Company’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eli Lilly and Company’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Eli Lilly and Company including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Eli Lilly and Company’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Eli Lilly and Company’s pipeline products

Reasons to buy

- Evaluate Eli Lilly and Company’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Eli Lilly and Company in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Eli Lilly and Company’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Eli Lilly and Company and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eli Lilly and Company
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Eli Lilly and Company and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Eli Lilly and Company Snapshot
Eli Lilly and Company Overview
Key Information
Key Facts
Eli Lilly and Company - Research and Development Overview
Key Therapeutic Areas
Eli Lilly and Company - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Eli Lilly and Company - Pipeline Products Glance
Eli Lilly and Company - Late Stage Pipeline Products
Eli Lilly and Company - Clinical Stage Pipeline Products
Eli Lilly and Company - Early Stage Pipeline Products
Eli Lilly and Company - Unknown Stage Pipeline Products
Eli Lilly and Company - Drug Profiles
dulaglutide
duloxetine hydrochloride DR
necitumumab
ramucirumab
cetuximab
abemaciclib
baricitinib
evacetrapib
insulin peglispro
ixekizumab
LY-2951742
odelepran hydrochloride
solanezumab
tadalafil
edivoxetine
galunisertib
blosozumab
emibetuzumab
erteberel
insulin lispro U100
LY-2409021
LY-2495655
LY-2510924
LY-2606368
LY-2623091
LY-2928057
LY-2940094
LY-2944876
LY-3015014
LY-3016859
LY-3023414
merestinib
olaratumab
pemetrexed disodium
ralimetinib mesylate
taladegib
Biologic 3 for Diabetes
Biologic 4 for Diabetes
Biologic 5 for Diabetes
Biologic for Anemia
Biologic for Crohn's Disease
Biologic for Diabetic Nephropathy
Biologic for Hypoglycemia
Biologic for Lupus
Biologic for Ulcerative Colitis
LY-2608204
LY-2780301
LY-2874455
LY-2922083
LY-2922470
LY-2969822
LY-2979165
LY-3002813
LY-3009120
LY-3022855
LY-3022856
LY-3025876
LY-3039478
LY-3041658
LY-3045697
LY-3050258
LY-3074828
LY-3079514
LY-3084077
LY-3090106
LY-3108743
LY-3113593
LY-3114062
LY-3127760
LY-3143753
LY-3154207
LY-3164530
LY-3185643
LY-3202626
LY-900014
Small Molecule for Hypertension
Small Molecule for Muscle Atrophy
Small Molecule to Agonize mGlu2/3 for Chronic Pain
cercosporamide
CPZEN-45
insulin lispro U200
insulin lispro U300
LLY-2707
LSN-2463359
LSN-2535717
LSN-2814617
LY-2109761
LY-2607540
LY-2857785
LY-3002813 + LY-2811376
Monoclonal Antibody Conjugate 1 for Cancer
Monoclonal Antibody Conjugate 2 for Cancer
Monoclonal Antibody Conjugate 3 for Cancer
ND-09759
Peptide for Type 2 Diabetes and Obesity
Small Molecule to Agonize TR-Beta for Dyslipidemia
Small Molecule to Antagonize mGlu5 for Pain
Monoclonal Antibodies for Cancer
Monoclonal Antibodies for Undisclosed Indication
Monoclonal Antibody Conjugates for Cancer
Small Molecule for Type 2 Diabetes
Small Molecules to Inhibit Beta Secretase for Alzheimer’s Disease
LY-3000328
Eli Lilly and Company - Pipeline Analysis
Eli Lilly and Company - Pipeline Products by Target
Eli Lilly and Company - Pipeline Products by Route of Administration
Eli Lilly and Company - Pipeline Products by Molecule Type
Eli Lilly and Company - Pipeline Products by Mechanism of Action
Eli Lilly and Company - Recent Pipeline Updates
Eli Lilly and Company - Dormant Projects
Eli Lilly and Company - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Eli Lilly and Company - Company Statement
Eli Lilly and Company - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Eli Lilly and Company - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Eli Lilly and Company, Key Information
Eli Lilly and Company, Key Facts
Eli Lilly and Company - Pipeline by Indication, 2015
Eli Lilly and Company - Pipeline by Stage of Development, 2015
Eli Lilly and Company - Monotherapy Products in Pipeline, 2015
Eli Lilly and Company - Combination Treatment Modalities in Pipeline, 2015
Eli Lilly and Company - Partnered Products in Pipeline, 2015
Eli Lilly and Company - Partnered Products/ Combination Treatment Modalities, 2015
Eli Lilly and Company - Out-Licensed Products in Pipeline, 2015
Eli Lilly and Company - Out-Licensed Products/ Combination Treatment Modalities, 2015
Eli Lilly and Company - Pre-Registration, 2015
Eli Lilly and Company - Filing rejected/Withdrawn, 2015
Eli Lilly and Company - Phase III, 2015
Eli Lilly and Company - Phase II, 2015
Eli Lilly and Company - Phase I, 2015
Eli Lilly and Company - Preclinical, 2015
Eli Lilly and Company - Discovery, 2015
Eli Lilly and Company - Unknown, 2015
Eli Lilly and Company - Pipeline by Target, 2015
Eli Lilly and Company - Pipeline by Route of Administration, 2015
Eli Lilly and Company - Pipeline by Molecule Type, 2015
Eli Lilly and Company - Pipeline Products by Mechanism of Action, 2015
Eli Lilly and Company - Recent Pipeline Updates, 2015
Eli Lilly and Company - Dormant Developmental Projects,2015
Eli Lilly and Company - Discontinued Pipeline Products, 2015
Eli Lilly and Company, Subsidiaries
Eli Lilly and Company, Key Manufacturing Facilities

List of Figures
Eli Lilly and Company - Pipeline by Top 10 Indication, 2015
Eli Lilly and Company - Pipeline by Stage of Development, 2015
Eli Lilly and Company - Monotherapy Products in Pipeline, 2015
Eli Lilly and Company - Partnered Products in Pipeline, 2015
Eli Lilly and Company - Out-Licensed Products in Pipeline, 2015
Eli Lilly and Company - Pipeline by Top 10 Target, 2015
Eli Lilly and Company - Pipeline by Top 10 Route of Administration, 2015
Eli Lilly and Company - Pipeline by Top 10 Molecule Type, 2015
Eli Lilly and Company - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll